title: PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
authors.affiliation: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; and.
authors.forename: Elise A
authors.initials: EA
authors.lastname: Chong
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
authors.forename: J Joseph
authors.initials: JJ
authors.lastname: Melenhorst
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
authors.forename: Simon F
authors.initials: SF
authors.lastname: Lacey
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
authors.forename: David E
authors.initials: DE
authors.lastname: Ambrose
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Gonzalez
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Levine
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
authors.forename: Carl H
authors.initials: CH
authors.lastname: June
authors.affiliation: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; and.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Schuster
mesh_terms: D000328:Adult; D019138:Antibodies, Blocking / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000276:immunology* / Q000628:therapy*; D008297:Male; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology
chemical_list: D019138:Antibodies, Blocking; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C000598123:CTL019 chimeric antigen receptor; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D011948:Receptors, Antigen, T-Cell; C582435:pembrolizumab